Company intelligence / Profile preview

HEM-iSMART E

Suwon, Gyeonggi-do, South Korea

Ownership: Private
Development stage: Other

Overview

HEM-iSMART is a South Korean biotechnology company specializing in personalized microbiome solutions and gut-brain axis health. The company utilizes its proprietary Personalized Microbiome Analysis System (PMAS) to analyze individual gut environments and provide tailored probiotic recommendations and health management services. Their business model integrates advanced diagnostic testing with functional food products to address conditions such as depression, anxiety, and metabolic health. HEM-iSMART aims to bridge the gap between microbiome research and consumer wellness through data-driven, individualized healthcare interventions.

Therapeutic areas: PsychiatryNeurologyMetabolic Disorders
Modalities: Diagnostic testMicrobiome-based therapy
Industry: Biotech

Partnerships

Amway (partnership for personalized probiotics)

Beyond the preview

Go deeper on HEM-iSMART E.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on HEM-iSMART E.

Explore the full profile